June 27, 2011 (Cleveland, Ohio) — Nearly two-thirds of outpatients with a normal LVEF when referred for echocardiography also had LV diastolic dysfunction, and moderate or severe diastolic dysfunction ...
Patients with heart failure (HF) who are started on sacubitril-valsartan (Entresto) in the hospital or soon after discharge will see a sharp drop in clinical risk whether their ejection fraction is ...
Please provide your email address to receive an email when new articles are posted on . In women with suspected ischemia, those with a high left ventricular ejection fraction have reduced risk for ...
PRAGUE, Czechia—In patients with an ejection fraction > 40% recovering from a worsening heart failure (HF) event, sacubitril/valsartan (Entresto; Novartis) led to greater reductions in NT-proBNP ...
A Tale of Two Citizens: A State Attorney General and a Hematologist Facilitate Translation of Research Into US Food and Drug Administration Actions—A SONAR Report The median age was 71 years, and 54% ...
Please provide your email address to receive an email when new articles are posted on . Sacubitril/valsartan showed benefit across the spectrum of left ventricular ejection fraction in stable patients ...
ENTRESTO The approval was based on data from the double-blind, parallel-group, active-controlled phase 3 PARAGON-HF trial. The Food and Drug Administration has ...
(UPDATED) There may be a benefit to early revascularization over medical therapy in patients with severe inducible ischemia on SPECT testing, regardless of their baseline left ventricular ejection ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback